LONDON & WARREN, N.J.–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced a New Drug Submission (NDS) to Health Canada for the review and approval of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% – a once-daily, dual-agent (combination) eye drop – for the treatment of presbyopia in adults. Presbyopia is the gradual lo